ERYTECH PHARMA - SPON ADR (ERYP)
US29604W1080 - ADR
ERYP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 587 industry peers in the Biotechnology industry. ERYP has a bad profitability rating. Also its financial health evaluation is rather negative. ERYP is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ERYP has reported negative net income.
ERYP had a negative operating cash flow in the past year.
In the past 5 years ERYP always reported negative net income.
ERYP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
ERYP has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for ERYP so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ERYP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ERYP remains at a similar level compared to 1 year ago.
The number of shares outstanding for ERYP has been increased compared to 5 years ago.
ERYP has a better debt/assets ratio than last year.
2.2 Solvency
ERYP has an Altman-Z score of -2.54. This is a bad value and indicates that ERYP is not financially healthy and even has some risk of bankruptcy.
ERYP's Altman-Z score of -2.54 is in line compared to the rest of the industry. ERYP outperforms 45.57% of its industry peers.
ERYP has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
ERYP's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. ERYP is outperformed by 71.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.54 |
ROIC/WACCN/A
WACC4.93%
2.3 Liquidity
ERYP has a Current Ratio of 3.65. This indicates that ERYP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.65, ERYP is doing worse than 61.67% of the companies in the same industry.
A Quick Ratio of 3.65 indicates that ERYP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.65, ERYP is doing worse than 60.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 99.68% over the past year.
Looking at the last year, ERYP shows a very strong growth in Revenue. The Revenue has grown by 59.04%.
Measured over the past years, ERYP shows a quite strong growth in Revenue. The Revenue has been growing by 14.60% on average per year.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q102.44%
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y14.6%
Revenue growth Q2Q198.12%
3.2 Future
The Earnings Per Share is expected to grow by 26.28% on average over the next years. This is a very strong growth
Based on estimates for the next years, ERYP will show a very negative growth in Revenue. The Revenue will decrease by -44.77% on average per year.
EPS Next Y22.35%
EPS Next 2Y26.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year16.44%
Revenue Next 2Y16.85%
Revenue Next 3Y-56.11%
Revenue Next 5Y-44.77%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
ERYP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ERYP. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ERYP's earnings are expected to grow with 26.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.28%
EPS Next 3YN/A
5. Dividend
5.1 Amount
ERYP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ERYTECH PHARMA - SPON ADR
NASDAQ:ERYP (6/28/2023, 7:00:02 PM)
0.78
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap26.61M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.65 | ||
| Quick Ratio | 3.65 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y22.35%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)59.04%
Revenue growth 3Y7.96%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y